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Background/aim: To investigate serum ischemia-modified albumin (IMA), oxidized low-density lipoprotein (ox-LDL) levels, and
paraoxonase 1 (PON1) activity in patients with diabetic foot.
Materials and methods: Thirty patients with diabetes mellitus (DM), 30 patients with diabetic foot (29 and 27 of these patients had
type 2 DM, respectively), and 30 healthy volunteers as the control group were included in the study. The patients with diabetic foot were
divided into 2 groups, as those who had or had not undergone lower extremity amputation. Serum PON1 activity, ox-LDL, and IMA
levels were measured.
Results: Serum PON1 activity was lower (P < 0.05) and ox-LDL levels were higher (P < 0.05) in the diabetic foot group than in the
control and diabetes groups. Albumin-adjusted IMA values were higher (P < 0.001) in the diabetic foot group compared to the diabetes
group. The postamputation levels of IMA were decreased compared to the preamputation condition (P < 0.05).
Conclusion: The low activity of PON1 and the high levels of ox-LDL and IMA may play an important role in the pathogenesis of
diabetic foot. The use of these parameters in the follow-up of patients with DM may prevent the development of diabetic foot. In order
to reach a definitive judgment, further studies with a larger number of subjects are necessary.
Key words: Diabetic foot, ischemia-modified albumin, oxidized low-density lipoprotein, paraoxonase 1, peripheral arterial disease

1. Introduction
Diabetes mellitus (DM) is a metabolic disease characterized
by hyperglycemia, resulting from defects in insulin secretion,
insulin action, or both. The chronic hyperglycemia of DM is
associated with long-term damage, dysfunction, and failure
of various organs, especially the eyes, kidneys, nerves, heart,
and blood vessels (1). Diabetic foot ulcers are estimated
to affect 15% of all patients with DM during their lifetime
(2). Ulceration, infection, gangrene, and lower extremity
amputation are complications often encountered in patients
with DM. These complications frequently result in extensive
morbidity, repeated hospitalizations, and high treatment
costs. The etiology of diabetic foot ulcers is multifactorial.
Risk factors identified include peripheral neuropathy,
vascular disease, limited joint mobility, foot deformities,
abnormal foot pressures, minor trauma, a history of
ulceration or amputation, and impaired visual acuity. Despite
considerable international efforts, DM continues to be the
most common underlying cause of nontraumatic lower
extremity amputations in the United States and Europe (3).
* Correspondence: muhtars@erciyes.edu.tr
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A prominent feature of type 2 DM is an atherogenic
dyslipidemia, characterized by an increase in triglyceriderich lipoproteins (very-low-density lipoproteins [VLDL]
and their remnants), a decrease in plasma levels of highdensity lipoprotein (HDL) cholesterol, and an increase
in the number of small dense low-density lipoprotein
particles (4). Oxidation of low-density lipoprotein (LDL)
is a key process in the early progression of atherosclerotic
diseases and DM complications (5). Paraoxonase 1 (PON1)
has been recognized as an antioxidant enzyme, which
plays an important role in preventing the accumulation of
the lipid peroxides on LDL. Inhibition of HDL oxidation
by PON1 could preserve the antiatherogenic functions of
HDL in reverse cholesterol transport, as well as protecting
LDL from oxidation (6,7).
The amino terminal end (N-terminal) of the albumin
molecule, especially the aspartyl-alanyl-histidyl-lysine
sequence, appears to be the primary binding site for
transitional metals, such as cobalt, copper, and nickel.
The N-terminal of albumin is modified during exposure
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to ischemic conditions, resulting in the formation of
ischemia-modified albumin (IMA) with a low binding
affinity to transitional metals. It has been reported that
IMA levels rise in diseases associated with ischemia (8).
The number of studies evaluating PON1 activity
and oxidized LDL (ox-LDL) levels in diabetic foot is
very limited (9,10). To our knowledge there is no study
concerning the IMA levels in patients with diabetic foot.
The aim of this study was to investigate serum IMA, oxLDL levels, and PON1 activity in patients with diabetic
foot and to evaluate whether there was any difference
between pre- and postamputation IMA values.
2. Materials and methods
2.1. Subjects
The study subjects consisted of 30 patients with DM
who had never suffered from diabetic foot complications
during their lifetime and 30 patients with DM who suffered
from diabetic foot. The patients with diabetic foot were
divided into 2 groups, according to who had or had not
undergone lower extremity amputation. We also included
30 volunteers who had routine laboratory results within
the reference interval, did not have any systemic disease,
and did not use any medication in a control group. The
study was conducted in the Department of Endocrinology,
Faculty of Medicine, Erciyes University between July 2009
and January 2011. The case-control study protocol was
approved by the Ethics Committee of Erciyes University
and the study was conducted according to the Declaration
of Helsinki. The participants were informed about the
study and informed consent was obtained.
2.2. Data collection
The duration of DM was accepted as the time from
the diagnosis of DM, according to American Diabetes
Association (ADA) criteria, to the time of the study.
The patients were evaluated for diabetic neuropathy and
retinopathy based on neurology and ophthalmology
findings, and for coronary artery disease based on their
history of myocardial infarction or electrocardiographic
findings. Patients with end-stage renal failure, a history of
thyroid or liver disease, or any malignancy were excluded
from the study. Body mass index (BMI) was calculated as
the ratio of weight (kg) to the square of height (m2).
The ulcers in patients with diabetic foot were graded
from 1 to 5 according to the presence of infection and/or
gangrene by using the Wagner (11) Classification (Grade
1: Presence of superficial ulcer confined to the epidermis;
Grade 2: Infection extending to the dermis, muscle,
tendon, and ligaments but no signs of osteomyelitis; Grade
3: Presence of deep soft tissue infection and osteomyelitis;
Grade 4: Gangrene localized to the distal foot; Grade 5:
Extensive gangrene). Examination findings and culture
and radiology results were used to classify the foot ulcers.

2.3. Laboratory analysis
All blood samples were collected into plain tubes
and anticoagulated (EDTA) tubes, as appropriate for
biochemical tests in the morning after an overnight fast.
Blood samples were taken twice from patients with DM
undergoing amputation for diabetic foot, once before
amputation and once at the end of the first week after
amputation. Hemoglobin A1c (HbA1c) was detected
with an HPLC system (Agilent 1100, Germany). After
centrifuging the blood samples for 10 min at 2000 × g,
serum glucose, creatinine, albumin, triglyceride (TG),
total cholesterol, LDL cholesterol (direct LDL cholesterol
measurement kit for patients, TG level was >400 mg/dL), and
HDL cholesterol were analyzed on an automatic analyzer
(Architect c8000, Abbott, USA), and C-reactive protein
(CRP) was measured by using immunonephelometry
(Dade Behring, Marburg, Germany).
Serum samples that were separated for PON1, oxLDL, and IMA measurements were stored at –70 °C until
analysis. PON1 activity in serum samples was determined
using the method described by Eckerson et al. (12).
Serum ox-LDL levels were measured using a sandwich
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions (Immündiagnostik,
Bensheim, Germany). LDL cholesterol values were
estimated by using Friedewald’s equation (13). Serum
IMA levels were measured by the method described by
Bar-Or et al. (14). Albumin-adjusted IMA values were
used to prevent the effect of low albumin level on IMA.
This value was obtained by multiplying the IMA value
with the coefficient determined by dividing the subject’s
serum albumin level to the mean serum albumin level of
the population (15).
2.4. Statistical analysis
IBM SPSS Statistics 20 was used to evaluate the data.
The Shapiro–Wilk test was used to determine whether
data distribution was normal. The summary statistics
of numerical variables with a normal distribution were
presented as mean ± standard deviation. The statistics
of numerical variables without a normal distribution
were presented as medians (25th–75th percentile). Study
groups with a normal distribution were compared with
one-way analysis of variance (ANOVA) and those without
a normal distribution were compared with Kruskal–Wallis
analysis. Parametric and nonparametric Tukey tests were
used for multiple comparisons. The independent t-test
or the Mann–Whitney U test was used respectively for
variables with and without a normal distribution when
comparing two groups. Summary statistics of categorical
variables were presented as percent (%), and the chisquare exact method was used to compare these variables.
Comparisons of two repeated measurements were
performed using the Wilcoxon t-test. The Spearman test
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was used for correlation analysis. P < 0.05 was considered
statistically significant.
3. Results
The descriptive characteristics of both the patient groups
and the control group are presented in Table 1. There was
no statistically significant difference in the comparison
of mean age between the control and diabetes groups
or between the diabetes and diabetic foot groups. BMI
values were higher in both patient groups than in the
control group. There was no significant difference in the
comparison of sex between the study groups. The duration
of DM and type 2 DM did not differ significantly between
the patient groups. The coronary artery disease, diabetic
retinopathy, and peripheral sensory neuropathy rates were
significantly higher in the diabetic foot group than the
diabetes group.
Biochemical parameters of study groups are given
in Table 2. Serum glucose, HbA1c, and TG levels were
significantly higher in both patient groups than in the
control group. Serum CRP and ox-LDL levels were found
to be significantly higher; PON1 activity and albumin
levels were found to be significantly lower in the diabetic
foot group compared to the control and diabetes groups.
Serum creatinine and albumin-adjusted IMA levels were
significantly higher in the diabetic foot group than the
diabetes group. Total cholesterol, LDL cholesterol, and
HDL cholesterol were significantly reduced in the diabetic
foot group compared to the diabetes group.
When foot ulcers were graded according to the Wagner
Classification there were 3 (10%) patients with Grade 1,
13 (43.3%) patients with Grade 2, 10 (33.4%) patients

with Grade 3, 1 (3.3%) patients with Grade 4, and 3 (10%)
patients with Grade 5. Lower extremity amputation was
performed on 9 (30%) of the patients with diabetic foot
and the foot ulcers were Grade 3 in 5 (55.6%), Grade 4 in 1
(11.1%), and Grade 5 in 3 (33.3%) of these patients.
As shown in Table 3 comparison of the subgroups of
the diabetic foot group as amputated or not amputated
revealed no significant difference in terms of HbA1c,
creatinine, TG, total cholesterol, LDL cholesterol, albuminadjusted IMA, and ox-LDL, while CRP levels were higher
(P = 0.022) and HDL cholesterol and albumin levels were
lower (P = 0.035, P = 0.049, respectively) in the amputated
group.
As shown in the Figure postamputation IMA values
were found to be lower compared with preamputation
IMA values (0.672 ± 0.108 vs. 0.773 ± 0.144, P < 0.05).
In contrast, preamputation albumin levels showed no
significant difference when compared to postamputation
albumin values (3.27 ± 0.51 vs. 3.41 ± 0.50, P > 0.05).
There was a negative correlation between ox-LDL and
PON1 in the diabetes group (P = 0.020, rho = –0.422). The
level of serum HDL cholesterol was negatively correlated
with the level of serum CRP in the diabetic foot group (P
= 0.023, rho = –0.415).
4. Discussion
Lifestyle changes have led to an increase in type 2 DM
and its chronic complications (16). In the literature
so far, studies have reported on concerns regarding
antioxidant status, lipid peroxidation, serum asymmetric
dimethylarginine, nitric oxide, and immune mediator
levels in patients with diabetic foot ulcers (17–21).

Table 1. Comparison of descriptive characteristics of both patient groups and control group.
Patient groups
Control (n = 30)

Diabetes (n = 30)

Diabetic foot (n = 30)

P

52.60 ± 8.76a

56.53 ± 8.91ab

58.67 ± 9.23b

0.033

16 (53.3)/14 (46.7)

15 (50)/15 (50)

17 (56.7)/13 (43.3)

0.964

BMI (kg/m2)

25.42 ± 2.71a

30.19 ± 4.24b

29.14 ± 5.21b

<0.001

Duration of DM (years)

-

11.73 ±5.53

13.27 ± 6.93

0.347

Type 2 DM

-

29 (96.6)

27 (90)

0.347

Coronary artery disease

-

5 (16.7)

13 (43.3)

0.047

Diabetic retinopathy

-

9 (30)

23 (76.6)

<0.001

Peripheral sensory neuropathy

-

16 (53.3)

28 (93.3)

<0.001

Age (year)
Sex
(male/female)

Data are presented as mean ± standard deviation or n (%). a,b: Significant findings between groups (P < 0.05) are marked with different
letters. BMI: Body mass index, DM: diabetes mellitus.
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Table 2. Biochemical parameters of study groups.
Parameters

Control (n = 30)

Diabetes (n = 30)

Diabetic foot (n = 30)

P

Glucose (mg/dL)

90.5 (84–98)

200 (153–231)

175.5 (142–216)

<0.001

HbA1c (%)

5.2 (4.6–5.8)

8.9 (7.9–10.7)

7.8 (7.1–9.1)

<0.001

Creatinine (mg/dL)

0.8 (0.7–0.9)a

0.92 (0.82–1.0)b

1.2 (0.97–1.43)c

<0.001

CRP (mg/L)

3.41 (3.27–3.41)a

3.34 (3.27–4.13)a

23 (7.14–73.6)b

<0.001

TG (mg/dL)

83 (73–106)

136 (96–190)

155 (116–224)

<0.001

Total cholesterol (mg/dL)

183.5 (175–192)

203 (184–223)

183 (160–196)

0.002

LDL cholesterol (mg/dL)

114.3 ± 12.9a

137.8 ± 34.0b

112.1± 22.9a

<0.001

HDL cholesterol (mg/dL)

48.99 ± 11.43a

42.93 ± 8.60b

33.37 ± 8.47c

<0.001

Albumin (g/dL)

4.16 ± 0.27

4.13 ± 0.37

3.56 ± 0.54

PON1 (U/L)

97.7 (56.4–149.1)

ox-LDL (ng/mL)

a

b

a

b

b

a

b

b

a

b

b

a

a

a

<0.001

b

74.8 (46.3–147.1)

71.5 (36.2–90.7)

0.025

123 (100–135)a

132 (109–170)a

175 (150–215)b

<0.001

IMA (ABS U)

0.395 ± 0.054a

0.478 ± 0.095b

0.721 ± 0.123c

<0.001

IMA (ABS U)

-

0.475 ± 0.093

0.660 ± 0.122

<0.001

♣

a

a

a

b

b

Data are presented as mean ± standard deviation or median (25th–75th percentile).
: Significant findings between groups (P < 0.05) are marked with different letters. PON1: paraoxonase 1, ox-LDL: oxidized lowdensity lipoprotein, IMA: ischemia-modified albumin, IMA♣: albumin-adjusted ischemia-modified albumin.
a,b,c

Table 3. Comparison of amputated and not amputated diabetic foot groups.
Diabetic foot (n = 30)
Parameters

Not amputated
diabetic foot (n = 21)

Amputated
diabetic foot (n = 9)

P

HbA1c (%)

7.8 ± 1.6

8.1 ± 1.9

0.711

Creatinine (mg/dL)

1.19 ± 0.33

1.44 ± 0.44

0.096

CRP (mg/L)

18.0 (6.34–43.25)

74.30 (27.30–101.90)

0.022

TG (mg/dL)

156 (105.5–250)

142 (115–224)

0.894

Total cholesterol (mg/dL)

186.05 ± 27.04

167.44 ± 31.86

0.113

LDL cholesterol (mg/dL)

114.4 ± 19.8

106.5 ± 29.5

0.394

HDL cholesterol (mg/dL)

35.48 ± 7.5

28.44 ± 8.96

0.035

Albumin (g/dL)

3.69 ± 0.51

3.27 ± 0.51

0.049

PON1 (U/L)

72.6 ± 35.7

58.9 ± 30.3

0.324

ox-LDL (ng/mL)

170 (147–210)

182 (149–258)

0.449

IMA (ABS U)

0.699 ± 0.109

0.773 ± 0.144

0.133

IMA (ABS U)

0.652 (0.587–0.726)

0.666 (0.529–0.690)

0.790

♣

Data are presented as mean ± standard deviation or median (25th–75th percentile). PON1: paraoxonase 1, ox-LDL:
oxidized low-density lipoprotein, IMA: ischemia-modified albumin, IMA♣: albumin-adjusted ischemia-modified
albumin.
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1.1
1.0

IMA (ABS U)

0.9
0.8
0.7
0.6
0.5
0.4
Pre amputation

Postamputation

Figure. Comparison of preamputation and postamputation IMA
values.

However, there have not been enough studies regarding
atherosclerosis-related parameters except routine lipid
tests such as TG, LDL cholesterol, HDL cholesterol, and
total cholesterol in patients with diabetic foot.
It has been reported that PON1 activity decreases in
patients with symptomatic peripheral arterial disease,
and low PON1 activity is associated with endothelial
dysfunction (22). Kasprzak et al. (23) reported low PON1
activity in patients with lower extremity necrosis due to
peripheral arterial disease. Lixandru et al. (9) also reported
decreased HDL cholesterol levels and PON1 activity in
patients with diabetic foot ulcers. We compared PON1
activity in the diabetic foot group not only with a control
group but also with a diabetes group. We found a low
activity of PON1 and a decreased level of HDL cholesterol
in the diabetic foot group, as reported in the literature.
The increase in inflammatory markers such as
CRP and serum amyloid A (SAA) in type 2 DM leads
to changes in HDL structure (24). These acute phase
reactants replace antioxidant enzymes of HDL, PON1, and
platelet-activating factor acetyl hydrolase (PAF-AH). HDL
becomes inadequate in protecting LDL from oxidation and
becomes a proinflammatory molecule (24,25). The acute
decrease in PON1 activity due to the acute inflammatory
event exacerbates LDL oxidation (6).
In this study, based on the negative correlation between
HDL cholesterol and CRP in patients with diabetic foot, we
suggest that high CRP levels may accompany the decrease
in HDL cholesterol values and PON1 activity.
Maintaining LDL cholesterol at less than 100 mg/dL is
widely encouraged in patients with DM; however, serum
ox-LDL levels have been found to increase in patients
with DM even when LDL cholesterol values are below 100
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mg/dL (26). It has been found that low HDL cholesterol
levels and high ox-LDL/LDL cholesterol ratios could affect
vascular calcification on the plain radiography in the feet
of hemodialysis patients (10). In another study, high serum
lipoprotein (a) levels in patients with gangrenous diabetic
foot lesions have been reported (27).
In this study, there was no significant difference in the
ox-LDL levels of the diabetes and control groups. This
result may be due to the negative correlation between the
ox-LDL levels and PON1 activity and may be interpreted as
LDL oxidation being prevented by PON1 in these patients.
We found high levels of ox-LDL in the diabetic foot group.
This finding might suggest that decreased PON1 activity
is responsible for the high ox-LDL values in patients with
diabetic foot. The low HDL cholesterol, increased oxLDL levels, and low PON1 activity may be mediators of
advanced atherosclerosis. Our study results suggest that
while LDL cholesterol is related to the development of
atherosclerosis in patients with DM, it is not as important
of a determinant as ox-LDL in the patients with diabetic
foot.
The first data regarding IMA levels in patients with DM
were reported by Piwovar et al. (28). The same study found
that chronic oxidative stress triggered by hyperglycemia
could increase IMA production by decreasing the cobaltbinding characteristic of albumin. Their study determined
higher IMA levels in the patients with DM compared with
the healthy control subjects, but no significant difference
in terms of IMA levels was determined among patients
with DM with various levels of vascular complication. It
was also reported that IMA values in patients with good
glycemic control (HbA1c of ≤7%) were lower than in those
with poor glycemic control (28).
IMA levels have been shown to increase in patients
with DM and even further in patients with diabetic
nephropathy (29) or diabetic retinopathy (30). It was
also reported that detecting microvascular hypoxia at an
early stage is important in preventing potential retinal
complications and IMA can be beneficial as an indicator
to determine diabetic retinopathy risk (30).
Another study found high IMA levels in patients with
lower extremity ischemia, along with serum albumin
levels within the reference range but no acute coronary
syndrome, and it was stated that IMA could be useful
for the diagnosis of peripheral ischemia (31). IMA levels
have been reported to increase in patients with type 2 DM
with peripheral arterial disease compared to those without
peripheral arterial disease. IMA has been shown to be an
independent risk factor for peripheral arterial disease (32).
Gaze et al. (33) reported that IMA levels are influenced
by changes in serum albumin levels and there is a strong
negative correlation between IMA and low albumin
levels (≤3.4 g/dL), although this is much less marked
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across the reference interval for albumin. Albumin levels
should be taken into account when interpreting IMA
levels. Low albumin can also be the cause of high IMA
levels in hypoalbuminemic patients besides the ischemia.
Therefore, the use of an albumin-adjusted correction has
been proposed.
In another study, IMA was shown to have high
sensitivity and a negative predictive value in excluding
acute coronary syndrome (34). In contrast to troponins
that are released when necrosis occurs in cardiac tissue,
IMA is regarded as a marker of myocardial ischemia (35).
IMA is not specific for cardiac ischemia and also increases
noncardiac ischemic disorders such as peripheral vascular
disease, end-stage renal disease, cerebrovascular disease,
and acute infections (8).
In this study, high IMA levels may be related to the
oxidative stress caused by hyperglycemia, as reported in
the literature. The fact that IMA levels are even higher
in patients with diabetic foot than the diabetes group
may be interpreted as a result of infection and peripheral
ischemia. The significant decrease in IMA levels following
amputation might be related to tissue reperfusion and the
removal of necrotic and infected tissue.
Nather et al. (36) reported that significant univariate
predictive factors for limb loss were age above 60 years,
stroke, ischemic heart disease, nephropathy, peripheral
vascular disease, peripheral sensorial neuropathy, HbA1c

level, gangrene, and infection. The results of another study
demonstrated that nephropathy, ischemic diabetic foot,
and admission fasting blood glucose of >200 mg/dL, as
well as history of previous amputation, are independent
risk factors for amputation (37). In our study, statistically
significant differences in CRP, HDL cholesterol, and
albumin levels were seen in the amputated group, and foot
ulcers in this group were graded from 3 to 5. Although
serum creatinine levels were higher and PON1 activity was
lower in the amputated group, there were no statistically
significant differences. The limitation of our study was
small sample size.
In conclusion, we suggest that low PON1 activity, high
ox-LDL, and IMA values may play an important role in
diabetic foot pathogenesis. The increased CRP levels and
decreased HDL cholesterol and albumin levels in patients
with diabetic foot may increase the risk of amputation. The
use of these parameters in the follow-up of patients with
DM may prevent the development of diabetic foot and
lower extremity amputations. In order to reach a definitive
judgment, further studies with a larger number of subjects
are necessary.
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